Professor of Precision Oncology
Dr Greystoke joined Newcastle University and the Northern Centre for Cancer Care in 2014 after 8 years spent at the University of Manchester/ Christie NHS Trust. He is one of 3 consultants that run the Sir Bobby Robson Early Clinical Trials Centre at the Freeman hospital in Newcastle, and has a special interest in the development of new anti-cancer drugs for patients with lung cancer. He is a member of Lung CSG, leads systemic therapy research for NSCLC in the North-East, with a portfolio of Phase I-IV studies, and is the sub-specialty lead for lung cancer for the North-East England and North Cumbria NIHR CRN. In addition he is the Principle Investigator of PROSPECT-NE a study assessing molecular profiles in patients referred for early clinical studies in Newcastle and he leads the Pharmacodynamic Biomarker team at the Northern Institute for Cancer Research, Newcastle University.